Active Biotech AB Interim report January - September 2016
November 11 2016 - 1:00PM
Laquinimod
-
The clinical trials CONCERTO, ARPEGGIO and
LEGATO-HD are progressing according to plan
-
The study results from the pivotal clinical
Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis
(RRMS) are expected in the first half of 2017
-
The study results from the pivotal clinical
Phase 2 ARPEGGIO study, evaluating laquinimod for the treatment of
primary progressive multiple sclerosis (PPMS), are expected in the
second half of 2017
-
Preclinical results concerning laquinimod were
presented at the ECTRIMS 2016 Congress held in London, UK, on
September 14-17, 2016
-
Special Protocol Assessment (SPA) for laquinimod
rescinded after discussions with the FDA
ANYARA
Tasquinimod, Paquinimod (57-57)
and SILC (ISI)
New share issue
-
The Board of Directors has today decided, based
on the authorization granted by the Annual General Meeting, to
implement a rights issue totaling approximately SEK 55 M
-
The issue is at no cost guaranteed in full by
the company's largest owner MGA Holding AB
Financial summary
SEK M |
July - Sept |
Jan
- Sept |
Full
Year |
|
2016 |
2015 |
2016 |
2015 |
2015 |
|
|
|
|
|
|
Net
sales |
4.1 |
5.2 |
12.0 |
11.3 |
16.3 |
Operating
loss |
-11.1 |
-22.2 |
-41.6 |
-149.7 |
-177.9 |
Loss for
the period |
-12.4 |
-23.4 |
-44.8 |
-152.7 |
-193.5 |
Loss per
share, before and after dilution (SEK) |
-0.14 |
-0.26 |
-0.50 |
-1.70 |
-2.15 |
Cash and
cash equivalents (at the end of the period) |
|
|
39.9 |
132.4 |
103.6 |
For further
information, please contact:
Tomas
Leanderson, President and CEO
Tel: +46 46 19 20 95
Hans Kolam, CFO
Tel: +46 46 19 20 44
|
Active
Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 05
|
The report is also available at
www.activebiotech.com.
Active Biotech AB Interim Report
Jan-Sept 2016
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2023 to Apr 2024